JPH01272515A - Hair producing agent - Google Patents
Hair producing agentInfo
- Publication number
- JPH01272515A JPH01272515A JP63101795A JP10179588A JPH01272515A JP H01272515 A JPH01272515 A JP H01272515A JP 63101795 A JP63101795 A JP 63101795A JP 10179588 A JP10179588 A JP 10179588A JP H01272515 A JPH01272515 A JP H01272515A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- compound
- hair
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims abstract description 22
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000003779 hair growth Effects 0.000 claims description 24
- -1 piperidino-3-sulfoxypyridinium hydroxide Chemical compound 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 10
- 239000006210 lotion Substances 0.000 abstract description 10
- 239000000443 aerosol Substances 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- YRIYHNRDKVBZDR-UHFFFAOYSA-N (2,4-diamino-6-piperidin-1-ylpyridin-1-ium-3-yl) hydrogen sulfate;hydroxide Chemical compound [OH-].NC1=C(OS(O)(=O)=O)C(N)=CC(N2CCCCC2)=[NH+]1 YRIYHNRDKVBZDR-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000499 gel Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000037308 hair color Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 229930007845 β-thujaplicin Natural products 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DBPWSSGDRRHUNT-SJFWLOONSA-N (8r,9s,10r,13s,14s,17s)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-SJFWLOONSA-N 0.000 description 1
- IATKKATWPOVYCC-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 IATKKATWPOVYCC-VMXHOPILSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- UYZQWKKNVBJVOF-UHFFFAOYSA-N 1-decoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCC UYZQWKKNVBJVOF-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- PXGPQCBSBQOPLZ-UHFFFAOYSA-N butanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCC(O)=O PXGPQCBSBQOPLZ-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940065346 hydroxyprogesterone acetate Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は発毛剤に関し、更に詳しくは、２−メチル−２
，４−ペンタンジオールを添加することにより、発毛効
果を高めた発毛剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a hair growth agent, more specifically, 2-methyl-2
, 4-pentanediol, the hair growth agent has an enhanced hair growth effect.
［従来の技術］
６−（１−ピペリジニル）−２，４−ピリミジンジアミ
ン−３−オキサイド［以下、化合物Ｉと称する。コ及び
２，４−ジアミノ−６−ピペリジノ−３−スルホキシピ
リジニウムヒドロキサイド［以下、化合物Ｉと称する。[Prior Art] 6-(1-Piperidinyl)-2,4-pyrimidinediamine-3-oxide [hereinafter referred to as Compound I]. and 2,4-diamino-6-piperidino-3-sulfoxypyridinium hydroxide [hereinafter referred to as Compound I].
］に優れた発毛効果があることは特開昭６２−５０１５
５８号及び米国特許公報第れ３９６１９号で報告されて
いる。] has an excellent hair growth effect as disclosed in Japanese Patent Application Laid-Open No. 62-5015.
No. 58 and US Pat. No. 39,619.
［発明が解決しようとする課題］
本発明の目的は、化合物Ｉ及び化合物■の発毛剤として
の効果をさらに高めることである。[Problems to be Solved by the Invention] An object of the present invention is to further enhance the effects of Compound I and Compound (2) as hair growth agents.
［課題を解決するための手段］
本発明者らは、上記事情に鑑み、更に優れた発毛効果を
発揮する製剤を開発すべく鋭意研究を進めた結果、化合
物Ｉ又は化合物■に２−メチル−２，４−ペンタンジオ
ールを添加することにより本発明の目的が達成されるこ
とを見出し、本発明を完成した。[Means for Solving the Problems] In view of the above circumstances, the present inventors conducted intensive research to develop a formulation that exhibits even better hair growth effects, and as a result, they added 2-methyl to Compound I or Compound ■. The present invention was completed based on the discovery that the object of the present invention can be achieved by adding -2,4-pentanediol.
すなわち、本発明は化合物Ｉ又は化合物■に２−メチル
−２，４−ペンタンジオールを添加するこきを特徴とす
る発毛剤である。That is, the present invention is a hair growth agent characterized by adding 2-methyl-2,4-pentanediol to Compound I or Compound (2).
本発明で用いる化合物Ｉ又は化合物■の配合量は、製剤
全体の０．０５〜５．０重量部、好ましくは、０．２〜
２．０重量部である。The amount of Compound I or Compound (2) used in the present invention is 0.05 to 5.0 parts by weight, preferably 0.2 to 5.0 parts by weight of the entire preparation.
It is 2.0 parts by weight.
また、２−メチル−２，４−ペンタンジオールの配合量
は、製剤全体の０．５〜３０重量部、好ましくは、１〜
２０重量部である。The amount of 2-methyl-2,4-pentanediol to be added is 0.5 to 30 parts by weight, preferably 1 to 30 parts by weight, based on the entire formulation.
It is 20 parts by weight.
この他必要に応じて、抗炎症剤（例えば、グリチルレチ
ン酸、グアイアズレン等）、末梢血管拡張剤（例えば、
ビタミンＥアセテート、ニコチン酸ベンジル、オタネニ
ンジンエキス、センブリ抽出エキス、トウガラシエキス
等）、副腎皮質ホルモン（例えば、酢酸ハイドロコーチ
シン、吉草酸ベタメタシン、酪酸プロピオン酸ハイドロ
コーチシン等）、抗ヒスタミン剤（例えば、塩酸ジフェ
ンヒドラミン、塩酸イソチペンジル等）、局所麻酔剤（
例えば、塩酸ジブカイン、塩酸リドカイン等）、角質溶
解剤（例えば、尿素、サリチル酸等）、油分（例えば、
スクワラン、イソプロピルミリステート、オリーブ油、
高級アルコール等）、卵胞ホルモン（例えば１７β−エ
ストラジオール、エストロン等）、黄体ホルモン（例工
ば、プロゲステロン、１７β−ヒドロキシプロゲステロ
ンアセテート等）、抗アンドロゲン剤（例えば、シブロ
チロンアセテート、４−アンドロステン−３−オン−１
７β−カルボキシリックアシッド等）、殺菌剤（例えば
、イ才つ、グルコン酸クロルヘキシジン、イソプロピル
メチルフェノール、第４級アンモニウム塩、ヒノキチオ
ール等）、保湿剤（例えば、ヒアルロン酸、コンドロイ
チン硫酸塩、プロピレングリコール、グリセリン、ジグ
リセリン等）、清涼剤（例えば、メントール、カンフル
等）、界面活性剤（例えば、ポリオキシエチレンソルビ
タン虐肪酸エステル、グリセリンモノ脂肪酸エステル、
プロピレングリフールモノ脂肪酸エステル等）、溶媒（
例えば、エチルアルコール、イソプロピルアルコール、
１．３−ブチレンゲリコール、プロピレングリフールジ
詣肪酸エステル、精製水等）、ゲル化剤（カルボキシビ
ニルポリマー、メチルセルロース、ヒドロキシプロピル
セルロース等）、ＰＲ調整剤（ジイソプロパツールアミ
ン、アンモニア、トリエタノールアミン、水酸化ナトリ
ウム等）、その他発毛剤に通常用いられる香料、酸化防
止剤、金属イオン封鎖剤、紫外線吸収剤、染料等を本発
明の効果を損なわない範囲で配合することができる。In addition, anti-inflammatory agents (e.g., glycyrrhetinic acid, guaiazulene, etc.), peripheral vasodilators (e.g.,
(vitamin E acetate, benzyl nicotinate, Panax ginseng extract, Japanese cabbage extract, hot pepper extract, etc.), adrenal corticosteroids (e.g., hydrocortiscin acetate, betamethacin valerate, hydrocortiscin propionate butyrate, etc.), antihistamines (e.g., diphenhydramine hydrochloride) , isothipendyl hydrochloride, etc.), local anesthetics (
For example, dibucaine hydrochloride, lidocaine hydrochloride, etc.), keratolytic agents (for example, urea, salicylic acid, etc.), oils (for example,
squalane, isopropyl myristate, olive oil,
(higher alcohols, etc.), follicular hormones (e.g., 17β-estradiol, estrone, etc.), progestin (e.g., progesterone, 17β-hydroxyprogesterone acetate, etc.), anti-androgens (e.g., cybrothyrone acetate, 4-androstene, etc.) 3-on-1
7β-carboxylic acid, etc.), bactericidal agents (e.g., Isaitsu, chlorhexidine gluconate, isopropylmethylphenol, quaternary ammonium salts, hinokitiol, etc.), moisturizers (e.g., hyaluronic acid, chondroitin sulfate, propylene glycol, glycerin, diglycerin, etc.), cooling agents (e.g., menthol, camphor, etc.), surfactants (e.g., polyoxyethylene sorbitan fatty acid ester, glycerin monofatty acid ester,
propylene glyfur monofatty acid ester, etc.), solvents (
For example, ethyl alcohol, isopropyl alcohol,
1.3-butylene gellicol, propylene glyfur di-fatty acid ester, purified water, etc.), gelling agents (carboxyvinyl polymer, methyl cellulose, hydroxypropyl cellulose, etc.), PR modifiers (diisopropanolamine, ammonia, triethanolamine, sodium hydroxide, etc.), other fragrances, antioxidants, sequestering agents, ultraviolet absorbers, dyes, etc. commonly used in hair growth agents can be blended within the range that does not impair the effects of the present invention. .
本発明の発毛剤は、通常用いられる方法（例えば第１１
改正日本薬局方に規定する方法等）に従って、ローショ
ン、乳液、クリーム、ゲル、エアゾール等の各種タイプ
の発毛剤に調製される。The hair growth agent of the present invention can be prepared by a commonly used method (for example,
It is prepared into various types of hair growth agents such as lotions, milky lotions, creams, gels, and aerosols according to the methods specified in the revised Japanese Pharmacopoeia.
［発明の効果コ
本発明により、化合物Ｉ及び化合物Ｉの発毛作用を著し
く高め、又化合物Ｉ及び化合物■の発毛作用を減するこ
となくその配合量を低減することができた。[Effects of the Invention] According to the present invention, the hair growth effect of Compound I and Compound I was significantly enhanced, and the amounts of Compound I and Compound 2 were able to be reduced without reducing their hair growth effect.
［実施例コ
以下、実施例と試験例を挙げて本発明を具体的に説明す
る。[Example] Hereinafter, the present invention will be specifically explained with reference to Examples and Test Examples.
（実施例１）
エチルアルコール７０重量部に化合物Ｉ Ｏ，５重量部
、２−メチル−２，４−ペンタンジオール１０重量部及
び精製水１９．５重量部を加えて撹拌溶解し、ローショ
ン剤を調製した。(Example 1) 5 parts by weight of Compound IO, 10 parts by weight of 2-methyl-2,4-pentanediol, and 19.5 parts by weight of purified water were added to 70 parts by weight of ethyl alcohol and dissolved with stirring to prepare a lotion. Prepared.
（実施例２）
化合物■の代わりに化合物Ｉを使用するほかは前記実施
例１に準じてローション剤を調製した。(Example 2) A lotion was prepared according to Example 1, except that Compound I was used instead of Compound (1).
（実施例３）
エチルアルコール５０ｆｉ 置部、２−メチル−２゜４
−ペンタンジオール５重量部、ポリオキシエチレン（２
０ンモノステアレ一ト２重量部を混合溶解し、これにカ
ルボキシビニルポリマー０．７重量部を分散させた後、
化合物ｌ０１５重量部、精製水４１．１重量部を添加し
、溶解した。(Example 3) Ethyl alcohol 50fi Okibe, 2-methyl-2゜4
- 5 parts by weight of pentanediol, polyoxyethylene (2 parts by weight)
After mixing and dissolving 2 parts by weight of monostearate and dispersing 0.7 parts by weight of carboxyvinyl polymer therein,
15 parts by weight of the compound and 41.1 parts by weight of purified water were added and dissolved.
この溶液にジイソプロパツールアミン０．７重量部を添
加し、撹拌混合してゲル剤を調製した。0.7 parts by weight of diisopropanolamine was added to this solution and mixed with stirring to prepare a gel.
（実施例４）
グリセリルモノステアレート５重量部、イソプロピルミ
リステート２重量部、スクワラン５重量部、流動パラフ
ィン５重量部、ポリオキシエチレン（２０）ソルビタン
モノステアレート４重量部、ブロビレングリコールモノ
イソステアレート４重量部、セチルアルコール２重量部
、ステアリルアルコール２重量部、ビタミンＥアセテー
ト０．２重量部、ヒノキチオール０．１重量部、グリチ
ルレチン酸０．２重量部を加温しながら撹拌して溶解し
た。(Example 4) 5 parts by weight of glyceryl monostearate, 2 parts by weight of isopropyl myristate, 5 parts by weight of squalane, 5 parts by weight of liquid paraffin, 4 parts by weight of polyoxyethylene (20) sorbitan monostearate, brobylene glycol monoiso Dissolve 4 parts by weight of stearate, 2 parts by weight of cetyl alcohol, 2 parts by weight of stearyl alcohol, 0.2 parts by weight of vitamin E acetate, 0.1 part by weight of hinokitiol, and 0.2 parts by weight of glycyrrhetinic acid by stirring while heating. did.
あらかじめ化合物１１重量部、２−メチル−２，４−ペ
ンタンジオ−ルア重量部、パラオキシ安息香酸エチル０
．１重量部、精製水６２．４重量部を加温しながら撹拌
溶解した液を前記溶液に加え、撹拌混合してローション
剤を調製した。In advance, 11 parts by weight of the compound, 0 parts by weight of 2-methyl-2,4-pentanediol, and 0 ethyl paraoxybenzoate.
．． A solution obtained by stirring and dissolving 1 part by weight of purified water and 62.4 parts by weight of purified water was added to the above solution, and the mixture was stirred and mixed to prepare a lotion.
（実施例５）
化合物Ｉの代わりに化合物■を使用するほかは前記実施
例４に準じてローション剤を調製した。(Example 5) A lotion was prepared according to Example 4, except that Compound (1) was used instead of Compound (I).
（実施例６）
化合物Ｉ ０１５重量部、β−エストラジオールｏ、
ｏｏｏｇ重量部、ヒノキチオール０．２重量部、グリチ
ルレチン酸０．２重量部、ビタミンＥアセテート０．２
重量部、酢酸ハイドロコーチシン０．００１６重量部、
エチルアルコール５５重量部、２−メチル−２，４−ペ
ンタンジオール５重量部、党−メントール０．５重量部
を撹拌して溶解した。(Example 6) Compound I 015 parts by weight, β-estradiol o,
ooog parts by weight, hinokitiol 0.2 parts by weight, glycyrrhetinic acid 0.2 parts by weight, vitamin E acetate 0.2 parts by weight
parts by weight, 0.0016 parts by weight of hydrocortiscin acetate,
55 parts by weight of ethyl alcohol, 5 parts by weight of 2-methyl-2,4-pentanediol, and 0.5 parts by weight of menthol were dissolved with stirring.
あらかじめ、センブリエキス３重量部、ニンジンエキス
１重量部、トウガラーシチンキ０．６重量部、ポリオキ
シエチレン（２０）ポリオキシプロピレン（６）デシル
テトラデシルエーテル４重量部、精製水２４．７９７６
重量部を撹拌して溶解した液を、前記溶液に加え、撹拌
混合してローション剤を調製した。In advance, prepare 3 parts by weight of Oriental japonica extract, 1 part by weight of carrot extract, 0.6 parts by weight of chili pepper tincture, 4 parts by weight of polyoxyethylene (20) polyoxypropylene (6) decyltetradecyl ether, and 24.7976 parts by weight of purified water.
A liquid obtained by stirring and dissolving parts by weight was added to the above solution, and the mixture was stirred and mixed to prepare a lotion.
（実施例７）
化合物Ｉの代わりに化合物■を使用するほかは前記実施
例６に準じてローション剤を調製した。(Example 7) A lotion was prepared according to Example 6, except that Compound (1) was used instead of Compound (I).
（実施例８）
ポリオキシエチレンソルビタンモノオレエート３重量部
と、２−メチル−２，４−ペンタンジオール１０重量部
、化合物ｌ０１５重量部及び精製水７２．５重量部を撹
拌し溶解する。(Example 8) 3 parts by weight of polyoxyethylene sorbitan monooleate, 10 parts by weight of 2-methyl-2,4-pentanediol, 15 parts by weight of the compound 10, and 72.5 parts by weight of purified water are stirred and dissolved.
これをエアゾール罐に入れ、これに液化石油ガス４重量
部を加圧充填し、エアゾール剤を調製した。This was placed in an aerosol can, and 4 parts by weight of liquefied petroleum gas was charged under pressure to prepare an aerosol agent.
（実施例９）
化合物Ｉの代わりに化合物■を使用するほかは前記実施
例８に準じてエアゾール剤を調製した。(Example 9) An aerosol was prepared in accordance with Example 8, except that Compound (1) was used instead of Compound (I).
（試験例）
化合物Ｉ及び化合物■の発毛試験
（１）被験試料の調製：実施例１に準じて、第１表に示
す処方で化合物■に関する試料１〜６を調製し、第２表
に示す処方で化合物■に関する試料７〜１２を調製した
。また、第１表及び第２表に示す処方でそれぞれの対照
試料１〜６を調製した。(Test Example) Hair growth test for Compound I and Compound ■ (1) Preparation of test samples: According to Example 1, samples 1 to 6 regarding Compound ■ were prepared according to the formulation shown in Table 1, and the results shown in Table 2 were prepared. Samples 7-12 for Compound (1) were prepared using the recipe shown. In addition, control samples 1 to 6 were prepared using the formulations shown in Tables 1 and 2.
（以下、余白）
第１表
第２表
※鍼頒瑞よ、１衾刑１
（２）供試動物： Ｃ３Ｈ系マウス（雄性、７週齢）１
０匹を一群とし、各群の動物について、その背部の２ｃ
ｍＸ３ｃｍの範囲をバリカンで除毛し試験に供した。(The following is the margin) Table 1 Table 2 *Acupuncturist, 1 punishment 1 (2) Test animal: C3H mouse (male, 7 weeks old) 1
0 animals as one group, and 2c of the back of each group of animals.
Hair was removed from an area of m x 3 cm using clippers and used for the test.
（３）発毛試験：
■被験試料１〜１２及び対照試料の各々にそれぞれ別個
の群の供試動物を割り当て、その除毛部に１日１回、０
．２ｄ塗布した。(3) Hair growth test: ■ Assign a separate group of test animals to each of the test samples 1 to 12 and the control sample, and apply 0% to the hair removal area once a day.
．． 2d was applied.
供試動物の毛の色は黒色で、除毛部の皮膚の色は灰色で
あり、その毛の成長と共に灰色から黒色に色調が変化す
ることから、毛の色の黒さの程度を下記のように測定し
て毛の成長の程度を評価した。The hair color of the test animal is black, and the skin color at the hair removal area is gray, and the color tone changes from gray to black as the hair grows, so the degree of blackness of the hair color is determined as follows: The degree of hair growth was evaluated by measuring as follows.
すなわち、分光色差計［例えば、高速分光色差計０ＭＳ
−１２００型、く株）村上色彩技術研究新製コを使用し
て、Ｌ”ａ′″ｂ′″表色系に基づく除毛直後の被験部
のび値、ａ０値、ｂ′″値と、試料塗布１０日後および
同２０日後の被験部のび値、ａ”値、ｂ９値を測定して
、それぞれの差ΔＬｒ、Δａ？、Δｂ”を算出し、ＤＥ
’ａｂ−（（Δビ）３＋（Δ ＊ ） ＠ ＋ （Δｂ
＋）＊）ｔ／ｎの式から色差ＤＥ”ａｂ値を求め、その
−群の平均値で毛の色の黒さを示した。That is, a spectrophotometer [for example, a high-speed spectrocolorimeter 0MS
-1200 model, Ltd.) Murakami Color Technology Research Co., Ltd.) was used to determine the elongation value, a0 value, b''' value of the test area immediately after hair removal based on the L"a""b" color system, Measure the elongation value, a'' value, and b9 value of the test area 10 days and 20 days after applying the sample, calculate the respective differences ΔLr, Δa?, Δb'', and DE
'ab-((Δbi)3+(Δ*) @+(Δb
The color difference DE''ab value was determined from the formula of +)*)t/n, and the average value of the - group was used to indicate the blackness of the hair color.
また、試料塗布後１０日後およ−び２０日後の被験部の
毛の成長の程度を肉眼により下記の６段階で評価した。Furthermore, the degree of hair growth in the test area 10 and 20 days after application of the sample was visually evaluated on the following 6 scales.
※１ 肉眼評価における判断基準
Ｏ：発毛が全く認められない
１：発毛している
２：硬毛が正常の約２５％生えている
３：硬毛が正常の約５０％生えている
４：硬毛が正常の約７５％生えている
５：硬毛が正常の約１００％生えているその結果を第３
表に示す。*1 Judgment criteria for visual evaluation O: No hair growth observed 1: Hair growth 2: Terminal hair growth of approximately 25% of the normal level 3: Terminal hair growth of approximately 50% of the normal level 4 : Terminal hair is growing at about 75% of normal level 5 : Terminal hair is growing at about 100% of normal level The result is 3rd.
Shown in the table.
■試料塗布２０日後、被験部の２ｃｍＸ ２ｃｍの範囲
の毛をバリカンで刈り取り、その重量を測定してその試
料による毛の成長量とした。20 days after application of the sample, hair in a 2 cm x 2 cm area of the test area was clipped with clippers, and its weight was measured to determine the amount of hair growth due to the sample.
毛の成長量（ｍｇ）と前項■で得た色差ＤＥ？ａｂ値の
関係を第１図に示す。Hair growth amount (mg) and color difference DE obtained in the previous section ■? The relationship between ab values is shown in FIG.
この図から両者は明らかに比例関係にあることがわかる
。From this figure, it can be seen that the two are clearly in a proportional relationship.
第 ３ 表
対照１と４は、本発明処方とその効果が同等であるが、
化合物Ｉ又は化合物Ｉの配合量が多い。Table 3 Controls 1 and 4 have the same effect as the formulation of the present invention, but
Compound I or the amount of compound I blended is large.
（表１．２参照）(See Table 1.2)
第１図は毛の成長量と色差ＤＥ”ａｂの関係を示すグラ
フである。
特許出願人 大正製薬株式会社
代理人 弁理士 北 川 富 造Figure 1 is a graph showing the relationship between the amount of hair growth and color difference DE"ab. Patent applicant Taisho Pharmaceutical Co., Ltd. Representative Patent attorney Tomizo Kitagawa
Claims (1)
ジアミン−３−オキサイド又は２，４−ジアミノ−６−
ピペリジノ−３−スルホキシピリジニウムヒドロキサイ
ドに２−メチル−２，４−ペンタンジオールを添加する
ことを特徴とする発毛剤。(1) 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 2,4-diamino-6-
A hair growth agent characterized by adding 2-methyl-2,4-pentanediol to piperidino-3-sulfoxypyridinium hydroxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10179588A JP2600794B2 (en) | 1988-04-25 | 1988-04-25 | Hair growth agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10179588A JP2600794B2 (en) | 1988-04-25 | 1988-04-25 | Hair growth agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01272515A true JPH01272515A (en) | 1989-10-31 |
| JP2600794B2 JP2600794B2 (en) | 1997-04-16 |
Family
ID=14310093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10179588A Expired - Fee Related JP2600794B2 (en) | 1988-04-25 | 1988-04-25 | Hair growth agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2600794B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0262818A (en) * | 1988-08-26 | 1990-03-02 | Katsuyoshi Aikawa | Hair-tonic composition |
-
1988
- 1988-04-25 JP JP10179588A patent/JP2600794B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0262818A (en) * | 1988-08-26 | 1990-03-02 | Katsuyoshi Aikawa | Hair-tonic composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2600794B2 (en) | 1997-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07316023A (en) | Hair tonic | |
| JPH08277209A (en) | Revitalizing hair tonic | |
| JP2733980B2 (en) | Hair restoration composition | |
| JP2001288043A (en) | Composition for scalp and hair | |
| JPH1179951A (en) | Tyrosinase activity promoter | |
| JP3314785B2 (en) | Minoxidil-containing hair restorer | |
| JPH01272515A (en) | Hair producing agent | |
| JPH06211632A (en) | Hair-growing agent | |
| JP2001139436A (en) | Hair tonic and grower | |
| JP2001288046A (en) | Composition for scalp and hair | |
| JPH10279437A (en) | Hair cosmetic | |
| JPH0971513A (en) | Hair tonic | |
| JPH04108722A (en) | Trichogenous agent | |
| JPH01132510A (en) | Hair tonic | |
| JP3536872B2 (en) | Hair restorer | |
| JP3496896B2 (en) | Hair restorer and hair cosmetic | |
| JPH059105A (en) | Hair grower | |
| JPH04234804A (en) | Hair restorer | |
| JP3520936B2 (en) | Hair restorer | |
| JPH04120011A (en) | Hair growing agent | |
| JPH01139523A (en) | Hair tonic agent | |
| JPH0449216A (en) | Melanin inhibitor | |
| JPH0753338A (en) | Hair tonic | |
| JPH1179950A (en) | Tyrosinase activity promoter | |
| JP2002145742A (en) | Hair tonic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |